Rempart Asset Management Inc. Sells 7,370 Shares of Johnson & Johnson (NYSE:JNJ)

Rempart Asset Management Inc. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 64.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,100 shares of the company's stock after selling 7,370 shares during the period. Rempart Asset Management Inc.'s holdings in Johnson & Johnson were worth $680,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. WealthTrak Capital Management LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. bought a new stake in Johnson & Johnson during the fourth quarter worth $29,000. Bay Harbor Wealth Management LLC purchased a new stake in Johnson & Johnson in the 4th quarter valued at $32,000. Conquis Financial LLC bought a new position in Johnson & Johnson during the 4th quarter valued at $33,000. Finally, Bernard Wealth Management Corp. purchased a new position in Johnson & Johnson during the 4th quarter worth $36,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

NYSE JNJ traded up $1.41 during trading on Friday, hitting $154.99. 15,529,047 shares of the company's stock traded hands, compared to its average volume of 7,975,488. The stock has a market capitalization of $372.92 billion, a price-to-earnings ratio of 23.31, a PEG ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The business has a 50 day moving average of $154.43 and a 200-day moving average of $153.63. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.36%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson's payout ratio is presently 57.84%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent analyst reports. Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Barclays decreased their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Raymond James cut their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Finally, Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Eleven analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average price target of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.